 <h1>Temodar Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>temozolomide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about temozolomide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Temodar.</p><h2>In Summary</h2><p><b>Common side effects of Temodar include:</b> leukopenia. <b>Other side effects include:</b> decreased hemoglobin.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to temozolomide: oral capsule</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, temozolomide (the active ingredient contained in Temodar) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking temozolomide:</p><p>
<i>Less common or rare</i>
</p><ul>
<li>Amnesia</li>
<li>black, tarry stools</li>
<li>blood in the urine or stools</li>
<li>convulsions</li>
<li>cough or hoarseness</li>
<li>fever or chills</li>
<li>lower back or side pain</li>
<li>muscle weakness or paralysis on one or both sides of the body</li>
<li>painful or difficult urination</li>
<li>pinpoint red spots on the skin</li>
<li>swelling of the feet or lower legs</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>chest pain</li>
<li>clay colored stools</li>
<li>cough</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>hives, itching, or skin rash</li>
<li>joint or muscle pain</li>
<li>nausea or vomiting</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>unusual tiredness or weakness</li>
<li>yellow skin or eyes</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of temozolomide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Anxiety</li>
<li>blurred or double vision</li>
<li>breast pain (in females)</li>
<li>burning or prickling feeling on the skin</li>
<li>confusion</li>
<li>diarrhea</li>
<li>difficulty with speaking</li>
<li>drowsiness</li>
<li>increased urge to urinate</li>
<li>loss of appetite</li>
<li>loss of muscle coordination</li>
<li>mental depression</li>
<li>runny or stuffy nose</li>
<li>trouble sleeping</li>
<li>unusual weight gain</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to temozolomide: intravenous powder for injection, oral capsule</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (Up to 33%), nausea (Up to 53%), vomiting (Up to 42%), diarrhea (16%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, stomatitis, taste perversion, dysphagia, dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal distension, fecal incontinence, gastrointestinal disorder, gastroenteritis, hemorrhoids<sup>[Ref]</sup></p><h3>General</h3><p>The most common side effects were alopecia, nausea, vomiting, anorexia, headache, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (Up to 41%), convulsions (Up to 23%), hemiparesis (18%), abnormal coordination (11%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, confusion, memory impairment, amnesia, paresthesia, somnolence, paresis, urinary incontinence, ataxia, abnormal gait, neuropathy, balance impairment, speech disorder, tremors, hemiparesis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (11%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Palpitation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (Up to 61%), asthenia (13%), fever (13%)</p>
<p><b>Common</b> (1% to 10%): Weakness, radiation injury, face edema, pain, hearing impairment</p>
<p><b>Uncommon</b> (0.1% to 1%): Otitis media, tinnitus, hyperacusis, earache, deafness, vertigo, impotence, vaginal hemorrhage, menorrhagia, amenorrhea, vaginitis, breast pain<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Adrenal hypercorticism<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea, upper respiratory tract infection, pharyngitis, sinusitis</p>
<p>Post-marketing surveillance: Interstitial pneumonitis, pneumonitis, alveolitis, pulmonary fibrosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (55 to 69%), rash (13 to 19%)</p>
<p><b>Common</b> (1% to 10%): Dry skin, erythema, pruritus, petechiae </p>
<p><b>Uncommon</b> (0.1% to 1%): Photosensitivity reaction, abnormal pigmentation, sweating increased</p>
<p>Post-marketing surveillance: Toxic epidermal necrolysis, Stevens-Johnson syndrome<sup>[Ref]</sup></p><p>A case of diffuse erythematous skin rash that progressed to an extensive full body desquamative skin rash has been reported.  Even though temozolomide was permanently discontinued, the patient continued to experience the rash on a long-term basis with periodic exacerbations.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, anxiety, depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Agitation, apathy, behavior disorder, hallucination, amnesia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (19 to 27%)</p>
<p><b>Common</b> (1% to 10%): Weight increase, weight decrease, hyperglycemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, back pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision blurred, diplopia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hemianopia, visual acuity reduced, vision disorder, visual field defect, eye pain, dry eyes<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infection, Herpes simplex, wound infection, candidiasis oral</p>
<p><b>Uncommon</b> (0.1% to 1%): Herpes zoster, influenza-like symptoms</p>
<p>Post-marketing surveillance: Opportunistic infections including Pneumocystis pneumonia<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Post-marketing surveillance: Secondary malignancies including myeloid leukemia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytopenia, hemorrhage, leukopenia, neutropenia, lymphopenia, febrile neutropenia, anemia</p>
<p>Post-marketing surveillance: Prolonged pancytopenia, myelodysplastic syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): ALT increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic enzymes increased, Gamma GT increased, AST increased</p>
<p>Post-marketing surveillance: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis</p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergic reaction</p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, micturition increased frequency</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysuria</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Temodar (temozolomide)" Schering Corporation, Kenilworth, NJ. </p><p id="ref_2">2. Pick AM,  Neff WJ,  Nystrom KK "Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma." Pharmacotherapy 28 (2008): 406-9</p><p id="ref_3">3. Villano JL,  Collins CA,  Manasanch EE,  Ramaprasad C,  van Besien K "Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide." Lancet Oncol 7 (2006): 436-8</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Temodar (temozolomide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: alkylating agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Temodar &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Temodar Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Glioblastoma Multiforme</li>
<li>Anaplastic Astrocytoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to temozolomide: intravenous powder for injection, oral capsule</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (Up to 33%), nausea (Up to 53%), vomiting (Up to 42%), diarrhea (16%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, stomatitis, taste perversion, dysphagia, dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal distension, fecal incontinence, gastrointestinal disorder, gastroenteritis, hemorrhoids<sup>[Ref]</sup></p><h3>General</h3><p>The most common side effects were alopecia, nausea, vomiting, anorexia, headache, and constipation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (Up to 41%), convulsions (Up to 23%), hemiparesis (18%), abnormal coordination (11%)</p><p><b>Common</b> (1% to 10%): Dizziness, confusion, memory impairment, amnesia, paresthesia, somnolence, paresis, urinary incontinence, ataxia, abnormal gait, neuropathy, balance impairment, speech disorder, tremors, hemiparesis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (11%)</p><p><b>Uncommon</b> (0.1% to 1%): Palpitation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (Up to 61%), asthenia (13%), fever (13%)</p><p><b>Common</b> (1% to 10%): Weakness, radiation injury, face edema, pain, hearing impairment</p><p><b>Uncommon</b> (0.1% to 1%): Otitis media, tinnitus, hyperacusis, earache, deafness, vertigo, impotence, vaginal hemorrhage, menorrhagia, amenorrhea, vaginitis, breast pain<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Adrenal hypercorticism<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, dyspnea, upper respiratory tract infection, pharyngitis, sinusitis</p><p>Post-marketing surveillance: Interstitial pneumonitis, pneumonitis, alveolitis, pulmonary fibrosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (55 to 69%), rash (13 to 19%)</p><p><b>Common</b> (1% to 10%): Dry skin, erythema, pruritus, petechiae </p><p><b>Uncommon</b> (0.1% to 1%): Photosensitivity reaction, abnormal pigmentation, sweating increased</p><p>Post-marketing surveillance: Toxic epidermal necrolysis, Stevens-Johnson syndrome<sup>[Ref]</sup></p><p>A case of diffuse erythematous skin rash that progressed to an extensive full body desquamative skin rash has been reported.  Even though temozolomide was permanently discontinued, the patient continued to experience the rash on a long-term basis with periodic exacerbations.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, anxiety, depression</p><p><b>Uncommon</b> (0.1% to 1%): Agitation, apathy, behavior disorder, hallucination, amnesia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (19 to 27%)</p><p><b>Common</b> (1% to 10%): Weight increase, weight decrease, hyperglycemia</p><p><b>Uncommon</b> (0.1% to 1%): Hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, back pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision blurred, diplopia</p><p><b>Uncommon</b> (0.1% to 1%): Hemianopia, visual acuity reduced, vision disorder, visual field defect, eye pain, dry eyes<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Infection, Herpes simplex, wound infection, candidiasis oral</p><p><b>Uncommon</b> (0.1% to 1%): Herpes zoster, influenza-like symptoms</p><p>Post-marketing surveillance: Opportunistic infections including Pneumocystis pneumonia<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Post-marketing surveillance: Secondary malignancies including myeloid leukemia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytopenia, hemorrhage, leukopenia, neutropenia, lymphopenia, febrile neutropenia, anemia</p><p>Post-marketing surveillance: Prolonged pancytopenia, myelodysplastic syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): ALT increased</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic enzymes increased, Gamma GT increased, AST increased</p><p>Post-marketing surveillance: Fatal and severe hepatotoxicity, elevation of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis</p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergic reaction</p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, micturition increased frequency</p><p><b>Uncommon</b> (0.1% to 1%): Dysuria</p><p id="ref_1">1. "Product Information. Temodar (temozolomide)" Schering Corporation, Kenilworth, NJ. </p><p id="ref_2">2. Pick AM,  Neff WJ,  Nystrom KK "Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma." Pharmacotherapy 28 (2008): 406-9</p><p id="ref_3">3. Villano JL,  Collins CA,  Manasanch EE,  Ramaprasad C,  van Besien K "Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide." Lancet Oncol 7 (2006): 436-8</p><h2>More about Temodar (temozolomide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: alkylating agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Temodar &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Temodar Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Glioblastoma Multiforme</li>
<li>Anaplastic Astrocytoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>